# EDGAR Filing Document

**Accession Number:** 0001420720
**File Stem:** 0001104659-25-060671
**Filing Date:** 2025-6
**Character Count:** 2832
**Document Hash:** 6a5e656ed2c0cd76202985a3baea9d1d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-060671.hdr.sgml**: 20250722

**ACCESSION NUMBER**: 0001104659-25-060671

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** iBio, Inc.
- **CENTRAL INDEX KEY:** 0001420720
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262797813
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 600 MADISON AVENUE, SUITE 1601
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022-1737
- **BUSINESS PHONE:** 302 355-0650

**MAIL ADDRESS:**
- **STREET 1:** 600 MADISON AVENUE, SUITE 1601
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022-1737

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** iBioPharma, Inc.
- **DATE OF NAME CHANGE:** 20080806

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** InB:Biotechnologies, Inc.
- **DATE OF NAME CHANGE:** 20071210

![](image_001.jpg)

June 18, 2025

  ****

***<u>VIA EDGAR</u>***

United States Securities

and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Lauren Hamill

---

| | |
|:---|:---|
| **Re:** | **iBio, Inc.** |
|  | **Registration Statement on Form S-3** |
|  | **Filed June 13, 2025**<br> **File No: 333-28800** |

---

Dear Ms. Hamill:

iBio, Inc. (the "**Registrant**") hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-28800), be accelerated by the U.S. Securities and Exchange Commission (the "**Commission**") to become effective on **Monday, June 23, 2025**, at **5:00 p.m**., Eastern Time, or as soon as reasonably practicable thereafter.

The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.

The Registrant hereby authorizes Leslie Marlow and/or Melissa Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (212) 885-5358 or Ms. Murawsky n at (215) 569-5732 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.

Thank you.

---

| | | |
|:---|:---|:---|
| Very truly yours, | Very truly yours, | Very truly yours, |
| IBIO, INC. | IBIO, INC. | IBIO, INC. |
| By: | /s/ Marc Banjak | /s/ Marc Banjak |
|  | Name: | Marc Banjak |
|  | Title: | Chief Legal Officer |

---

cc: Leslie Marlow, Blank Rome LLP Melissa Murawsky, Blank Rome LLP